Forskolin

SKU: orb1304821

Description

Forskolin is a labdane diterpene that activates adenylate cyclase (EC50=0.5 μM), elevating intracellular cAMP. This activity underpins its broad research use in studying cardiac inotropy, platelet aggregation, hypertension, and nuclear receptor (PXR/FXR) signaling in both cellular and animal models.

Research Area

Cell Biology, Epigenetics & Chromatin, Metabolism Research, Neuroscience, Signal Transduction

Key Properties

• CAS Number: 66575-29-9
• MW: 410.50
• Purity: 99.96%
• Formula: C₂₂H₃₄O₇
• SMILES: CC(=O)O[C@H]1[C@@H](O)[C@@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C
• Target: Autophagy,Adenylyl Cyclase,PKC,AChR,FXR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.00 mg/mL (7.31 mM);DMSO:245.00 mg/mL (596.83 mM);H2O:Insoluble;Ethanol:15.00 mg/mL (36.54 mM)

Bioactivity

• Target IC50:
  Adenylyl cyclase:0.5 μM (cell free)|adenylyl cyclase (type I):0.5 μM (EC50)|MCF-7 cells:63.3 μM
• In Vivo:
  METHODS: To assay anti-tumor activity in vivo, Forskolin (4-5 mg/kg in PBS/DMSO solution (15:1)) was injected intraperitoneally into BALB/c nude mice bearing murine multiple myeloma tumor MOPC315, and was administered on the 2nd/4th/6th day after tumor cell injection. RESULTS: All mice eventually developed tumors, but Forskolin significantly delayed tumor growth in vivo. Compounds that increase cAMP may have therapeutic potential in the treatment of multiple myeloma. METHODS: To investigate the effect of Forskolin on retinal inflammation under diabetic conditions, Forskolin (50 mg/kg) was administered by gavage once weekly for twelve weeks to C57BL/6 mice in the STZ-induced diabetes model. RESULTS: Retinal glucose concentrations were increased in both diabetic control and Forskolin-treated groups compared to normal controls, but due to down-regulation of glucose transporter protein 1 expression, the Forskolin-treated group was only about 68.06% of the diabetic control group. ICAM-1 and TNF-α expression was up-regulated in the Forskolin-treated and diabetic control groups compared to the normal control group, but the expression levels of these two inflammatory factors in the Forskolin-treated group were 68.75% and 75.37% of those in the diabetic control group, respectively.
• In Vitro:
  METHODS: Rat adrenal medullary chromosomal tumor cells PC12 were treated with Forskolin (0.01-10 µM) for 3-48 h. The growth inhibition of the cells was detected by MTT. RESULTS: The cell viability decreased rapidly after treatment with 10 µM Forskolin (88.4% after 6 h and 60.5% after 48 h). METHODS: Human myeloma cells U266, H929, INA-6, RPMI 8226 and OPM-2 were treated with Forskolin (1-100 µM) for 72 h. Cell death was detected by Flow Cytometry. RESULTS: Forskolin dose-dependently induced cell death in human myeloma cells, with U266, OPM-2 and INA-6 being more sensitive than H929 and RPMI 8226 cells. METHODS: Human IL-2-dependent leukemia cells Kit 225 and human leukemia cells MT-2 were treated with Forskolin (1-100 μM) for 20 min, and cAMP concentration was measured by ELISA. RESULTS: Forskolin induced an up-regulation of cAMP levels, which reached a maximum level between 50-100 μm.
• Cell Research:
  Kit 225 or MT-2 cells were treated with 1, 5, 10, 20, 50, or 100 μM Forskolin for 20 min at 37 °C. Cells were lysed and clarified by centrifugation, and the concentration of cAMP was detected by direct cAMP ELISA. Optical density was measured at 405 nm, and the concentration of intracellular cAMP was calculated using a weighted four parameter logistic curve according to the manufactures instructions .
• Animal Research:
  Forskolin was dissolved in dimethyl sulfoxide (DMSO) and injected intraperitoneally into neonatal mice at postnatal days 4 (P4) and 5 (P5). Mice injected with DMSO served as the controls. The treated mice were euthanized at P6, and their retinas were isolated for whole-mount immunohistochemistry (IHC). We first tested the effect of different concentrations of forskolin on the survival rate and retinal vasculature and determined the optimal concentration, 1.0 μg/50 μL (0.3 mg/kg) at P4 and 1.5 μg/50 μL (0.5 mg/kg) at P5, used to compare the retinal vascular phenotypes between WT mice and Mrp4-deficient mice . . After acclimatization for 2 weeks, animals were randomly divided into four groups of eight rats each and treated for six consecutive weeks as follows: The first group was treated with CCl4 (50% CCl4/corn oil; 0.5 mL·kg 1, i.p.) twice a week to induce liver fibrosis. The second group was given forskolin only at a dose of 10 mg·kg 1, i.p., dissolved in a DMSO/saline solution (1:49) five times a week. The third group was given both CCl4 and forskolin. The dose of forskolin used here was based on the results of our preliminary study. The fourth group served as the normal control, receiving vehicles only. At 24 h after the last injection, blood samples were collected from the retro‐orbital plexus after light anesthesia with sodium pentobarbital (50 mg·kg 1, i.p.). Serum was separated by centrifugation at 3000× g for 10 min and was used for the assessment of liver functions. Rats were killed by cervical dislocation, and livers were removed and weighed. A portion of liver tissue was washed and homogenized to obtain a 20% (w·v 1) homogenate, which was used for assessment of oxidative stress, inflammatory and fibrogenic markers. Another portion was placed in formalin for immunohistochemical and histopathological analyses. The remainder was stored at 80°C, together with the 20% homogenate, until needed .

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Coleonol, Colforsin, Adenylate Cyclase, Adenylyl cyclase, Adenylyl cyclase (AC), Adenylylcyclase, cancer, cAMP, antiaggregatory, antihypertensive, Autophagy, FSK, FXR, exosome, Forskolin, inhibit, Inhibitor, NR1H4, notropic, pregnane, X receptor, PXR, prostate

Compound Identifiers

PubChem CID

13361560